COVID-19 & CancerFreeGuest Editorial CCC19 data point to extensive use of hydroxychloroquine, azithromycin, or both, by patients with cancer and COVID-19 May 29, 2020Vol.46 No.22By Otis W. Brawley
COVID-19 & CancerFreeGuest Editorial CCC19 bridging the knowledge gap for patients with COVID-19 and cancerFirst results to be heard at 2020 ASCO Annual Meeting May 22, 2020Vol.46 No.21By Rana R. McKay, Toni K. Choueiri, Brian I. Rini and Jeremy L. Warner
COVID-19 & CancerFreeGuest Editorial Let’s not form blue ribbon panels to study disparities in COVID-19 deathsInstead, let’s find the will to act May 22, 2020Vol.46 No.21By Robert A. Winn and Katherine Y. Tossas
COVID-19 & CancerFreeGuest Editorial SARS-CoV-2 and oncology drugsWhat do we mean when we talk about value? May 15, 2020Vol.46 No.20By Garth W. Strohbehn, Daniel A. Goldstein and Mark J. Ratain
COVID-19 & CancerFreeGuest Editorial With the COVID-19 pandemic, the cancer clinical trials—they are a-changing May 08, 2020Vol.46 No.19By Gregory Masters, Nicholas J. Petrelli and Kandie Dempsey
COVID-19 & CancerFreeGuest Editorial Embracing the increasing value of eHealth in patient-centered cancer care during the COVID-19 pandemic and beyond May 08, 2020Vol.46 No.19By Frank J. Penedo and Joshua Kronenfeld
COVID-19 & CancerFreeGuest Editorial COVID-19 and community cancer careA Panorama of a Catastrophe May 08, 2020Vol.46 No.19By Debra Patt and Michael Kolodziej
COVID-19 & CancerFreeGuest Editorial Cancer doesn’t wait—we are treating cancer patients now May 01, 2020Vol.46 No.18By Richard Bold and Timothy Donahue
COVID-19 & CancerFreeGuest Editorial The pandemic of COVID-19 and its effect on clinical trials in the communityHow do we move forward? May 01, 2020Vol.46 No.18By James N. Atkins
COVID-19 & CancerFreeGuest Editorial Under the onslaughts of COVID-19, Montefiore deployed a PPE strategy for patients—PREVENT/PROTECT/ENABLE May 01, 2020Vol.46 No.18By Balazs Halmos, Roman Perez-Soler, Stuart Packer, Mary G. LaRocca, Bruce Rapkin, Shalom Kalnicki and Joseph Sparano
